The information on this site is intended for audiences
of the United States.

Close the layer

You are leaving www.ftc-tdf-preprems.com

By following this link, you are leaving this website. These websites are not controlled by the FTC-TDF Sponsor(s). FTC-TDF Sponsor(s) is not responsible for their content or your use of them.

Close the layer

Site under construction

These sites are managed outside of the FTC-TDF Shared REMS Website and will be available at a later time.

Close the layer

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 PrEP should be used only:

  • A. As part of a comprehensive HIV-1 prevention strategy that includes other preventive measures since emtricitabine/tenofovir disoproxil fumarate is not always effective in preventing the acquisition of HIV-1 infection
  • B. In individuals who have been counseled to strictly adhere to their emtricitabine/tenofovir disoproxil fumarate daily dosing schedule since the effectiveness of emtricitabine/tenofovir disoproxil fumarate in reducing the risk of acquiring HIV-1 infection is strongly correlated with adherence and measurable drug levels
  • C. In individuals who have a confirmed negative HIV-1 test prior to initiating and routinely while taking emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
  • D. All of the above

Which of the following statements is false?

  • A. Emtricitabine/tenofovir disoproxil fumarate should be used for HIV-1 PrEP only in individuals confirmed to be HIV-1 negative
  • B. Emtricitabine/tenofovir disoproxil fumarate is indicated for HIV-1 pre-exposure prophylaxis to reduce the risk of acquiring HIV-1 infection through injection drug use
  • C. Women taking emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP should not breastfeed their babies if acute HIV-1 infection is suspected
  • D. Emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP is not always effective in preventing HIV-1 infection

Which of the following items are not included on the Checklist for Prescribers: Initiation of Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis (PrEP)?

  • A. Perform HBV screening test
  • B. Perform testing for TB
  • C. Confirm negative HIV-1 status of the individual
  • D. Confirm creatinine clearance is ≥60 mL/min

Hepatic function should be monitored closely in:

  • A. HBV-infected patients who discontinue emtricitabine/tenofovir disoproxil fumarate
  • B. All people taking emtricitabine/tenofovir disoproxil fumarate
  • C. All people who discontinue emtricitabine/tenofovir disoproxil fumarate
  • D. None of the above

In clinical trials evaluating emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP, which of the following adverse reactions was not common?

  • A. Abdominal pain
  • B. Headache
  • C. Dizziness
  • D. Decreased weight

Emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP is indicated only for:

  • A. Men who are at risk for sexually acquired HIV-1 infection
  • B. Adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV-1 infection by any means
  • C. Adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV-1 infection through injection drug use
  • D. Adults and adolescents weighing at least 35 kg who are at risk for sexually acquired HIV-1 infection

The Agreement Form for Initiating Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis (PrEP) provides which of the following information:

  • A. A list of activities that put individuals at risk for sexually acquired HIV-1 infection
  • B. A confirmation that the prescriber has discussed the risks and benefits of using emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP with the uninfected individual
  • C. A signature from the individual asserting that the prescriber has explained the risks and benefits of taking emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP, including the need for adherence and a comprehensive prevention strategy, which includes safer sex practices
  • D. All of the above

To help emtricitabine/tenofovir disoproxil fumarate Sponsor(s) and the FDA understand who has viewed this training, please tell us the following


Report completion of training for emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP

Participate in a Knowledge, Attitude, and Behavior (KAB) survey to assess the use and understanding of emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP

Thank you


Incorrect. Please try again.

Try Again

Correct

Next